Overall asthma control: The relationship between current control and future risk

Research output: Contribution to journalArticle

Standard

Overall asthma control: The relationship between current control and future risk. / Bateman, Eric D.; Reddel, Helen K.; Eriksson, Göran; Peterson, Stefan; Ostlund, Ollie; Sears, Malcolm R.; Jenkins, Christine; Humbert, Marc; Buhl, Roland; Harrison, Tim W.; Quirce, Santiago; O'Byrne, Paul M.

In: Journal of Allergy and Clinical Immunology, Vol. 125, No. 3, 2010, p. 600-608.

Research output: Contribution to journalArticle

Harvard

Bateman, ED, Reddel, HK, Eriksson, G, Peterson, S, Ostlund, O, Sears, MR, Jenkins, C, Humbert, M, Buhl, R, Harrison, TW, Quirce, S & O'Byrne, PM 2010, 'Overall asthma control: The relationship between current control and future risk', Journal of Allergy and Clinical Immunology, vol. 125, no. 3, pp. 600-608. https://doi.org/10.1016/j.jaci.2009.11.033

APA

Bateman, E. D., Reddel, H. K., Eriksson, G., Peterson, S., Ostlund, O., Sears, M. R., ... O'Byrne, P. M. (2010). Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology, 125(3), 600-608. https://doi.org/10.1016/j.jaci.2009.11.033

CBE

Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, Jenkins C, Humbert M, Buhl R, Harrison TW, Quirce S, O'Byrne PM. 2010. Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology. 125(3):600-608. https://doi.org/10.1016/j.jaci.2009.11.033

MLA

Vancouver

Author

Bateman, Eric D. ; Reddel, Helen K. ; Eriksson, Göran ; Peterson, Stefan ; Ostlund, Ollie ; Sears, Malcolm R. ; Jenkins, Christine ; Humbert, Marc ; Buhl, Roland ; Harrison, Tim W. ; Quirce, Santiago ; O'Byrne, Paul M. / Overall asthma control: The relationship between current control and future risk. In: Journal of Allergy and Clinical Immunology. 2010 ; Vol. 125, No. 3. pp. 600-608.

RIS

TY - JOUR

T1 - Overall asthma control: The relationship between current control and future risk

AU - Bateman, Eric D.

AU - Reddel, Helen K.

AU - Eriksson, Göran

AU - Peterson, Stefan

AU - Ostlund, Ollie

AU - Sears, Malcolm R.

AU - Jenkins, Christine

AU - Humbert, Marc

AU - Buhl, Roland

AU - Harrison, Tim W.

AU - Quirce, Santiago

AU - O'Byrne, Paul M.

PY - 2010

Y1 - 2010

N2 - Background: Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective: This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler*) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods: The percentage of patients with Global Initiative for Asthma defined controlled asthma over time was assessed for budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies; higher dose inhaled corticosteroid (ICS), same dose ICS/long-acting beta(2)-agonist (LABA), and higher dose ICS/LABA plus short-acting beta(2)-agonist. The relationship between baseline ACQ-5 and exacerbations was investigated. A Markov analysis examined the transitional probability of change in control status throughout the studies. Results: The percentage of patients achieving asthma control increased with time, irrespective of treatment; the percentage Controlled/Partly Controlled at study end was at least similar to budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies: higher dose ICS (56% vs 45%), same dose ICS/LABA (56% vs 53%), and higher dose ICS/LABA (54% vs 54%). Baseline ACQ-5 score correlated positively with exacerbation rates. A Controlled or Partly Controlled week predicted at least Partly Controlled asthma the following week (>= 80% probability). The better the control, the lower the risk of an Uncontrolled week. The probability of an exacerbation was related to current state and was lower with budesonide/formoterol maintenance and reliever therapy. Conclusions: Current control predicts future risk of instability and exacerbations. Budesonide/formoterol maintenance and reliever therapy reduces exacerbations versus comparators and achieves at least similar control. (J Allergy Clin Immunol 2010;125:600-8.)

AB - Background: Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective: This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler*) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods: The percentage of patients with Global Initiative for Asthma defined controlled asthma over time was assessed for budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies; higher dose inhaled corticosteroid (ICS), same dose ICS/long-acting beta(2)-agonist (LABA), and higher dose ICS/LABA plus short-acting beta(2)-agonist. The relationship between baseline ACQ-5 and exacerbations was investigated. A Markov analysis examined the transitional probability of change in control status throughout the studies. Results: The percentage of patients achieving asthma control increased with time, irrespective of treatment; the percentage Controlled/Partly Controlled at study end was at least similar to budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies: higher dose ICS (56% vs 45%), same dose ICS/LABA (56% vs 53%), and higher dose ICS/LABA (54% vs 54%). Baseline ACQ-5 score correlated positively with exacerbation rates. A Controlled or Partly Controlled week predicted at least Partly Controlled asthma the following week (>= 80% probability). The better the control, the lower the risk of an Uncontrolled week. The probability of an exacerbation was related to current state and was lower with budesonide/formoterol maintenance and reliever therapy. Conclusions: Current control predicts future risk of instability and exacerbations. Budesonide/formoterol maintenance and reliever therapy reduces exacerbations versus comparators and achieves at least similar control. (J Allergy Clin Immunol 2010;125:600-8.)

KW - exacerbations

KW - Asthma control

KW - ACQ

KW - GINA

U2 - 10.1016/j.jaci.2009.11.033

DO - 10.1016/j.jaci.2009.11.033

M3 - Article

VL - 125

SP - 600

EP - 608

JO - Journal of Allergy and Clinical Immunology

T2 - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 1097-6825

IS - 3

ER -